Esperion Therapeutics, Inc. (ESPR)

1.9900 -0.1400 (-6.57%) 收市：04:00PM EDT

Esperion Therapeutics, Inc.

3891 Ranchero Drive
Suite 150
Ann Arbor, MI 48108
United States
734 887 3903
https://www.esperion.com

版塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
全職員工: 240

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Sheldon L. Koenig	President, CEO & Director	1.28M	無	1966
Dr. JoAnne Micale Foody FACC, M.D.	Chief Medical Officer	856.87k	無	1965
Mr. Eric J. Warren R.Ph.	Chief Commercial Officer	718.86k	無	1972
Mr. Benjamin Halladay M.B.A.	Chief Financial Officer	無	無	1986
Mr. Glenn P. Brame	Chief Technical Operations Officer	無	無	1958
Mr. Benjamin O. Looker J.D.	General Counsel & Corporate Secretary	550.35k	無	1982
Tiffany Aldrich M.B.A.	Associate Director of Corporate Communications	無	無	無
Ms. Betty Jean Swartz	Chief Business Officer	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

公司管治

截至 2024年4月1日 止，Esperion Therapeutics, Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：4；董事會：5；股東權利：8；現金賠償：9。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。